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Abstract
Rapidly increasing trend of thyroid cancer incidence has turned this disease into a global 
concern. An estimated number of 64,300 new cases of thyroid cancer occurred in men 
and women in 2016, which represents 3.8% of all new cancer cases of USA (https://seer.
cancer.gov/statfacts/html/thyro.html). Thus,  there  is a high possibility  for every physi-
cian  to encounter a  case of  thyroid cancer during his/her professional  lifetime.  In  this 
chapter, we  clarified  epidemiology,  different  categories,  and  new  approaches  toward 
diagnosis and management of thyroid cancer.
Keywords: thyroid cancer, epidemiology, differentiated thyroid cancer, undifferentiated 
thyroid cancer, thyroid nodule
1. Detailed epidemiology of thyroid cancer
As the most common endocrine cancer and fifth most common cancer in women, thyroid can-
cer includes approximately 1–1.5% of all new cases of cancer diagnosed annually in the USA 
based on previous data [1–3]. Thyroid  cancer  is more prevalent  among women and  those 
with positive family history of thyroid disease. Some prior studies have reported a world-
wide increasing trend for thyroid cancer incidence in recent decades [4]. Annual percent 
change (APC) is a commonly used indicator for the assessment of changes in incidence. Based 
on US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) pro-
gram, it has been reported 2.4% from 1980 to 1997 and 6.6% from 1997 to 2009 in both genders 
for thyroid cancer (data available at http://seer.cancer.gov/statfacts/html/thyro.html).
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
According to 2009–2013 data, the rate of new cases of thyroid cancer was 13.9 per 100,000 men 
and women per year (Figure 1). Table 1 summarizes number of new cases per 100,000 persons 
by race/ethnicity and sex. A recently published study on adolescent cancer incidence during 
1975–2012 has reported a 2.12% increase for females and 1.59% for males between 15 and 19 
years of age [5]. However, there is a study indicating that thyroid cancer incidence trend has 
slowed following release of American Thyroid Association (ATA) guideline in 2009 [6, 7]. It 
has been reported that overall thyroid cancer incidence had an increasing trend about 8% per 
year from 2000 to 2009. But APC showed a deceleration about 3% in men and 2.8% in women, 
which was confined to tumors less than 2.9 cm of size for women [7].
Also, thyroid cancer-related mortality was estimated to consist 0.3% of all cancer-related 
deaths in 2016. A 5-year survival rate of 98.1% has been reported for thyroid cancer. Despite 
increasing trend of incidence, thyroid cancer mortality has a relatively stable rate about 0.5 
cases per 100,000 persons both from 1973 to 2002 and 2009 to 2013 [8, 9].
In conclusion, it seems that thyroid cancer has been following an increasing trend in the past 































New Cases of Thyroid cancer
Figure 1. Thyroid cancer incidence in time (http://seer.cancer.gov/statfacts/html/thyro.html).
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that modern diagnostic techniques and strategies or in the other words “overdiagnosis” is 
in charge for this increasing trend [8, 10]. Others believe that environmental factors such 
as various irradiations and changes in lifestyle can be considered as the reasons for this true 
increase [11–14]. Regardless of the nature, this increase has turned thyroid cancer to a world-
wide health problem, which involves more attention and efforts toward diagnosis and proper 
management.
2. Categories of thyroid malignancies
Three are some different classifications for thyroid cancers. Previously and more commonly, 
thyroid gland malignancies were used  to be categorized  to  three  types: differentiated  thy-
roid cancers (such as papillary and follicular thyroid cancers), anaplastic carcinomas, and rare 
types of thyroid cancer (like medullary thyroid cancer). A newly released classification cat-
egorizes thyroid malignancies to two main follicular-derived and neuroendocrine C-cell–
derived types [1], which will be discussed in detail in following lines. Figure 2 illustrates this 
classification in order for better clarification.
Thyroid Cancers 
Follicular-derived Neuroendocrine C-cell-derived 
Differentiated Anaplastic 
Medullary Thyroid cancer 
Well-Differentiated Poorly-Differentiated 
1. Papillary Thyroid cancer 
2. Follicular Thyroid cancer 
3. Hurthle cell thyroid cancer 
Figure 2. Classification of thyroid malignancies.
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2.1. Follicular-derived thyroid cancers
Follicular-derived  thyroid  cancers  have  two main  subtypes:  differentiated  and  anaplastic 
cancers.
2.1.1. Differentiated thyroid cancers
Consisting approximately 95% of all thyroid cancers, differentiated thyroid cancer is the most 




2.1.1.1. Papillary thyroid cancer
Accounting for 70–90% of well-differentiated thyroid cancers and 80–85% of follicular cell-
derived thyroid cancers [16], papillary  thyroid cancers  (PTCs) are  the most prevalent  type 
of thyroid cancers [17]. Incidence of papillary thyroid cancer has increased along with recent 
increase in incidence of thyroid cancers. Experts believe that this increase is related to higher 




with increase in age [19]. Papillary thyroid cancer can also occur in children [19, 20].




increase in weight, 5 cm increase in waist or hip circumference, and 0.1 unit increase in waist-
to-hip ratio were associated with 30, 5, 5, and 14% greater risks of thyroid cancer, respectively 
[21]. Estrogen is also another potential risk factor for papillary thyroid carcinoma, which justi-
fies the sex difference for thyroid nodules and carcinoma [22]. Hepatitis C infection has been 
mentioned as a potential  risk  factor  for  thyroid cancer; however, more studies are needed 
to  confirm  this  association  [23].  It  is  not  exactly  clear  that  which  factor(s)  are  important 
and mainly contributed to the recent increase in thyroid cancer incidence.
Papillary thyroid cancer has the best overall prognosis [1]; however, there are some static 





tion; pre-, intra-, and post-operative.
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1. Pre- or intra-operative prognostic factors:








[24]; however, approved in some previous ones [18]. It has been concluded that male gen-
der has a moderate prognostic value in PTC patients; however, there are studies with con-
trast findings [34].




• Extrathyroid  extension:  it  is  one  of  the most  important prognostic  factors  for PTC  [36]. 
Grossly  significant  extrathyroid  extension  based  on  intra-operative  evidences  is  one 
of the most reliable prognostic factors.
• Clinical lymph node metastasis: not only the presence of lymph node metastasis is impor-






tivity  in  carcinoma. Ki-67  labeling  index  (LI)  is generally  low  in PTC patients; however 
patients with high Ki-67 labeling index are more likely to show recurrence or persistent 
disease and to die from carcinoma [24, 37]. High Ki-67 LI is considered as an independent 
prognostic factor for DFS and cause-specific survival (CSS) [37, 38].
• BRAF V600E mutation: many previous studies have mentioned that PTC with BRAF mu-




predictor of cancer recurrence [43].
• Poor differentiation and aggressive variants: patients with poorly differentiated PTC are 
known for their poor prognosis [24]. Poorly differentiated papillary thyroid carcinoma has 
been discussed as a separate section.
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Dynamic prognostic  factors  are based on  changes  in  serum  thyroglobulin  (Tg)  and  thyro-
globulin antibody (TgAb) after total thyroidectomy, which help with estimation of recurrence 
and cause-specific survival (CSS) of PTC patients.
• Tg-doubling  time  (Tg-DT):  for  the  first  time  in  2011,  Tg-doubling  time  was  proposed 




















• Stage I (Any T, Any N, M0): the tumor can be of any size (any T) and may or may not have 
spread to nearby lymph nodes (any N). It has not spread to distant sites (M0).
• Stage II (Any T, Any N, M1): the tumor can be of any size (any T) and may or may not have 
spread to nearby lymph nodes (any N). It has spread to distant sites (M1).
Papillary thyroid cancer in patients 45 years and older:
Stage I (T1, N0, M0): the tumor is 2 cm or less across and has not grown outside the thyroid 
(T1). It has not spread to nearby lymph nodes (N0) or distant sites (M0).




T3, N0, M0: the tumor is larger than 4 cm across or has grown slightly outside the thyroid 
(T3), but it has not spread to nearby lymph nodes (N0) or distant sites (M0).
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T4a, any N, M0: the tumor is any size and has grown beyond the thyroid gland and into 
nearby tissues of the neck (T4a). It might or might not have spread to nearby lymph nodes 
(any N). It has not spread to distant sites (M0).




Stage IVB (T4b, Any N, M0):  the  tumor  is of any size and has grown either back  toward 
the spine or into nearby large blood vessels (T4b). It might or might not have spread to nearby 
lymph nodes (any N), but it has not spread to distant sites (M0).





able data on the best approach for management are related to retrospective evaluations, large 
national registry studies, and meta-analysis but not randomized clinical trials (RCTs) [48–50]. 
Only RCTs are able to exactly determine the optimal treatment, such as extent of surgery, in PTC 
patients.  It  has been  estimated  that  a  large number  about  3000  to  5000 patients  are needed 
to be randomized for evaluation of cause-specific mortality, which is not actually possible.
Decision-making  for  primary  treatment  are  depended  on  preoperative  assessments  such 
as  clinical,  imaging  and  histological  evaluations.  Treatment  choices  are  based  on  location 
and extent of disease.
Figure 3  illustrates algorithm for primary treatment of patients with differentiated thyroid 
carcinomas. Recommendations of 2015 American Thyroid Association (ATA) guidelines are 
excellent reference as they are more conservative than before [51].
According to this guideline, unifocal tumors which are smaller than 4cm with no evidence 
of extrathyroidal extension or lymph node metastasis are resolvable by lobectomy. Previous stud-
ies have shown that bilateral or unilateral resections are associated with similar long-term sur-
vival [48, 52–54]. For patients with papillary microcarcinoma (less than 1 cm) without evidence 
of cervical lymph node metastasis, nonsurgical management is considered as an option [55, 56].
Surgical  and  pathological  findings  are  applied  shortly  after  surgery  for  deciscion-making 
on the possible need for thyroid hormone replacement therapy or radioiodine ablation or 
both. This assessment is based on well-known TNM staging which determines mortality but 




(Tables 2 and 3)  is  a  reliable  predictor  for  the  course  of  differentiated  thyroid  carcinoma 
treated with thyroidectomy alone or radioiodine remnant ablation [57–60].
Radioiodine therapy (RAI Tx): Previously application of radioactive iodine was  justified by 
the need for elimination thyroid normal tissue remnants. It is also considered as adjuvant 
treatment for destroying occult neoplastic cells within the thyroid remnant or throughout 
the body. This issue has been challenged recently because of short-term morbidity and pos-
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TSH suppression: TSH stimulates proliferation of normal thyrocytes and some malignant cells; 
so TSH suppression has been used as a treatment after surgery [62]. This approach significantly  





eration of malignant cells [66].




At the time of primary treatment














• V600EBRAF-mutated, intrathyroid, 1–4 cm, primary tumor
• V600EBRAF-mutated microcarcinoma, multifocal with extrathyroid extension
(3) ATA high risk (>20% recurrence)
Papillary thyroid cancer
• Gross extrathyroid extension
• Distant metastases
• Lymph node metastasis at least 3 cm in largest diameter
Follicular thyroid cancer
• >4 foci of vascular invasion
Table 2. Recurrence risk stratification at the time of primary treatment as a function of the response to treatment.











with those of papillary thyroid carcinoma.
2.1.1.3. Hurthle cell carcinoma
Oncocytic follicular cells of thyroid, known as Hurthle cells, which were first described by Karl 
Hürthle are the origin of Hurthle cell carcinoma (HCC) [70, 71]. They can be found in both 
benign  and  malignant  conditions  of  thyroid.  Histologic  differentiation  between  Hurthle 
cell  adenoma and  carcinoma can be definitely made only after  the  evaluation of  resection 
specimen by the presence or absence of vascular or capsular invasion, which is the hallmark 
of HCC [72]. HCC represents 3% of all thyroid cancers [73].
There  are  two  types  of  Hurthle  cell  carcinoma;  minimally  invasive  carcinomas  are  fully 
encapsulated tumors with microscopically identifiable foci of capsular or vascular invasion  
During follow-up
(1) Excellent response (1–4% recurrence)
• Imaging negative for disease recurrence
• Serum thyroglobulin concentration lower than 0.2 ng/mL basal or higher than 1 ng/mL TSH stimulated




(3) Biochemical incomplete response (20% recurrence)
• Imaging negative for disease recurrence
• Serum thyroglobulin concentration higher than 1 ng/mL basal or higher than 10 ng/mL TSH stimulated, or 
increasing thyroglobulin antibody concentrations
(4) Structural incomplete response (50–85% recurrence)
• Structural (neck ultrasound, CT, or MRI) or functional (whole-body scan or 18F-fluorodeoxyglucose PET) evi-
dence of disease in imaging studies
Table 3. Recurrence risk stratification over time as a function of the response to treatment.
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(<4  foci)  and  widely  invasive  tumors,  which  have  extensive  vascular  invasion  (>4  foci) 
and extrathyroidal invasion. Patients with minimally invasive carcinomas usually experience 
a better prognosis  [73]. Overall, older patients and those with larger tumor size, extrathy-









• Intermediate  risk:  vascular  invasion, minimal  extrathyroidal  extension,  or  >5 metastatic 
lymph nodes (0.2–3 cm).
• High risk: macroscopic extrathyroidal extension, incomplete tumor resection, distant  





As  other  differentiated  thyroid  cancers,  the  main  treatment  for  HCC  is  surgery.  Since 
the preoperative diagnosis of HCC is impossible by cytology, determining the initial extent 
of surgery and whether further surgical resection (completion thyroidectomy) involves post-
operative histological evaluation [70]. So, the first step is a thyroid lobectomy in the primary 
surgery unless the pathological features guide us to total thyroidectomy. Presence of domi-
nant contralateral nodule, nodule size greater than 4 cm or preexisting diminished thyroid 
hormone production requiring thyroid hormone therapy are another indication for total thy-
roidectomy [51].






and trend of thyroglobulin levels over time.
Radioiodine therapy (RAI Tx): Benefit of RAI Tx for HCC patients has remained as a question 
because a small number of studies have evaluated this treatment. Generally, RAI Tx is not 
routinely recommended for patients at low risk of recurrence.
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External beam radiation therapy (EBRT): In patients with clinically evident gross extrathyroidal 
extension that is incompletely resected, external beam radiation therapy (EBRT) can be con-
sidered  as  a  treatment  option. However,  potential  benefit  of  radiation  should be weighed 
against potential complications, such as dental decay, tracheal stenosis, esophageal stricture, 
osteonecrosis, fibrosis, and xerostomia [76].
2.1.1.4. Poorly differentiated thyroid cancer
Introduced by Sakamoto et al., this group of thyroid cancers fall between well-differentiated 
thyroid cancers (WDTC) and anaplastic thyroid cancer (ATC) in terms of both morphologic 





typical papillary thyroid cancer.
The most challenging issue in diagnosis of PDTC is lack of a precise definition. So, in 2006 
a group of experts set diagnostic criteria for PDTC in Turin, Italy [84]. As the most acceptable 
criteria, the 2006 Turin criteria are as following:
(1)  A solid/trabecular/insular pattern of growth
(2)  Absence of conventional nuclear features of papillary carcinoma
(3)  Presence  of  at  least  one  of  the  following  features:  convoluted  nuclei,  mitotic  activity 
(≥3×10 HPF), necrosis
PDTCs  are  usually  at  an  advanced  stage,  usually  extrathyroidal  extension  and  extensive 
local invasion, at the time of diagnosis [85]. They can be metastasized  to  regional  lymph 
nodes (50–85%), and distantly (36–85%), most commonly to the lung (14–54%), and bones 
(18–33%) [86, 87]. Survival rates are remarkably lower than in patients with WDTC [85, 87, 
88]. Patients more than 45 years of age and those with cervical lymph node invasion, tumor 
necrosis, local recurrence, mitotic index greater than 3 per 10 high-power fields, tumor size 
greater than 4 cm, and distant metastasis at the time of diagnosis have poorer prognosis 
[89–92][13, 31–34].
2.1.1.4.1. Management
Since  PDTC  is  rare,  the  best  treatment  option  for  treatment  remains  inconclusive.  Most 
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2.1.2. Anaplastic thyroid cancer (undifferentiated thyroid cancer)
Anaplastic thyroid cancer (ATC) is a rare and lethal form of thyroid cancer, which is respon-
sible  for  1.7–2% of  all  thyroid  cancers.  It usually  involves patients  in  their  sixth or  seventh 
decade of life and has a median survival of 5 months and less than 20% of patients are alive 1 
year after diagnosis. Geographical prevalence of ATC has a wide range from 1.3 to 9.8% [94–96].
ATC is considered to be originally derived from follicular cells resulted from dedifferentia-
tion. About  80% of ATC presents  in  patients with  long-standing  goiter, which  is  possibly 
in the setting of an undiagnosed well-differentiated thyroid cancer [95]. In most of the cases, 
ATC usually presents with a rapidly enlarging neck mass and local symptoms such as neck 
pain, dysphagia, dyspnea, and hoarseness [97]. Symptoms can be related to invasion of tumor 
to neighboring structures  such as  recurrent  laryngeal nerve  (RLN), parasympathetic  chain 
(causing Horner’s syndrome), or even carotid arteries (causing stroke). About 40% of patients 
usually present with lymphadenopathy and up to 43% have distant metastasis, most com-






a thorough discussion in order to have information on the impact of disease on their quality 
of life and also the potential benefit of participating in clinical trials [97]. The physician should 
also hold discussions around “do not  resuscitate”  (DNR) or “allow natural death”  (AND) 
with patients to decrease ambiguity in emergency situations, which require life-supporting 




Stage IVA (T4a, Any N, M0): the tumor is still within the thyroid (T4a). It might or might not 
have spread to nearby lymph nodes (any N), but it has not spread to distant sites (M0).
Stage IVB (T4b, Any N, M0): the tumor has grown outside the thyroid (T4b). It might or might 
not have spread to nearby lymph nodes (any N), but it has not spread to distant sites (M0).










malities which causes delay in diagnosis and consequently in treatment. As the diagnosis 
is  established,  staging  should  be  done  as well  as  the  assessment  of  airway  by  fiberoptic 
laryngoscopy.
Referring the patient to a center with experience with anaplastic thyroid cancer is highly 
recommended. An expert head and neck surgeon should assess the patient to determine if 
the primary  tumor  is  resectable. Early after  resection,  external beam radiation with  radio-
sensitizing  drugs,  like  taxanes  with  or  without  platin  or  anthracycline  (chemoradiation). 





or is stabilized by tracheostomy should preferably be enrolled in a clinical trial or undergo 
systemic chemotherapy by cytotoxic drugs [1].
Recently, targeted treatment has been suggested; for example prescription of BRAF inhibi-
tors in patients with BRAFV600E-mutated anaplastic thyroid cancer [103]. Dabrafenib, which is 
a selective BRAF inhibitor, trametinib, lenvatinib, rapamycin, and microtubule inhibitors are 
among the drugs being evaluated in ATC patients.
Patients and their family members should be informed of poor prognosis of the disease. Some 
patients should be transferred to a sanatorium if they do not wish to be treated or their per-
formance is poor.
2.2. Neuroendocrine C-cell–derived thyroid cancer
Accounting for 1–2% of all thyroid cancers, medullary thyroid cancer is relatively uncom-











Stage I (T1, N0, M0): the tumor is 2 cm or less across and has not grown outside the thyroid 
(T1). It has not spread to nearby lymph nodes (N0) or distant sites (M0).
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Stage II: one of the following applies:








T4a, any N, M0: the tumor is any size and has grown beyond the thyroid gland and into 
nearby tissues of the neck (T4a). It might or might not have spread to nearby lymph nodes 
(any N). It has not spread to distant sites (M0).




Stage IVB (T4b, Any N, M0):  the  tumor  is of any size and has grown either back  toward 
the spine or into nearby large blood vessels (T4b). It might or might not have spread to nearby 
lymph nodes (any N), but it has not spread to distant sites (M0).




As  other  thyroid  cancers,  surgery  is  the mainstay  for MTC management;  however,  imag-
ing and diagnosis before surgery are necessary for determining the best surgical interven-
tion [1]. As the diagnosis of MTC is made, the patient should undergo neck ultrasonography 
and tumor markers (calcitonin and carcinoembryonic antigen) evaluation.
In  addition,  it  should  be  determined  if  the  disease  is  sporadic  or  associated with MEN  2 
syndrome, because patients with MEN 2 may have pheochromocytoma or primary hyper-
parathyroidism or both. So, biochemical testing should be considered for ruling out pheo-
chromocytoma  or  primary  hyperparathyroidism  in  MTC  patients  with  unknown  status 
of germline RET mutation. If the patient has primary hyperparathyroidism, a total thyroid-
ectomy should be done including parathyroidectomy. For patients with pheochromocytoma, 
adrenalectomy should be prioritized to thyroidectomy. Patients with hereditary MTC should 
be referred to a genetic counselor so that only necessary family members undergo testing 
for lowering related costs [1]. Family members with germline RET mutation benefit from pro-
phylactic thyroidectomy [105].
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If preoperative calcitonin levels are higher than 146 pmol/L, work up should be done for dis-










limit  further  surgical  interventions  due  to  fibrosis  as  well  as  affecting  the  quality  of  life 
of patients.
Patients should be managed with active surveillance by both ultrasonography and serial 
evaluation of tumor markers to guide further surgical treatment. Patients with normal lev-
els of tumor markers and imaging after surgery should be followed up annually and those 
with  persistent  tumor markers  should  be  observed more  closely.  Patients with  calcitonin 
and CEA doubling time within 6 months have a shorter overall survival time [107].
3. Assessment and treatment of thyroid nodules
Thyroid nodules are usually  the first presenting  feature of a  thyroid cancer. So evaluation 
of thyroid nodules is of a great importance.
Size  plays  a  notable  role  in  determining  the  need  of  fine  needle  aspiration  (FNA) 
for a thyroid nodule; however, ultrasound features can provide valuable clues regarding 
malignancy of nodules [108]. These are hypoechogenicity, a solid internal structure, irreg-
ular margins, microcalcifications, taller-than-wide shape, and evidence of extrathyroidal 
extension or cervical lymphadenopathy for papillary thyroid cancers. Nodules which do 
not have these characteristics can be followed up without FNA until the nodule remains 
small [1].
Follicular thyroid cancer and follicular variant of papillary thyroid cancers are more often 
round and isoechoic with regular margins. A larger size and increased intranodular vascular-
ity on color or power Doppler imaging are also predictive of malignancy [109–112].
The  2015 ATA  guideline  has  bolded  the  role  of  ultrasound  in  diagnosis  and  approach 
to thyroid nodules (Figure 4)  [51].  Concurrent  risk  factors  of  thyroid  cancer  including 
cough,  neck  pain,  change  in  voice,  presence  of  a  firm mass,  history  of  childhood  neck 
radiation, or familial thyroid cancer should be considered and in these cases FNA is rec-
ommended regardless of ultrasound characteristics. ATA recommends biopsy for nodules 
larger than 1 cm.
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